Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 1, 2008, Pages 82-85

  Colanardi, Maria Cristina ^a   Nettis, Eustachio ^a,b   Traetta, Pierluigi ^a   Daprile, Carmela ^a   Fitto, Carmela ^a   Aloia, Anna Maria ^a   Di Leo, Elisabetta ^a   Ferrannini, Antonio ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ARYLACETIC ACID DERIVATIVE; ARYLPROPIONIC ACID DERIVATIVE; BETA LACTAM ANTIBIOTIC; BROMELAIN; CARDIOVASCULAR AGENT; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; FENAMIC ACID DERIVATIVE; GASTROINTESTINAL AGENT; HORMONE; LOCAL ANESTHETIC AGENT; MACROLIDE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARECOXIB; PLACEBO; PYRAZOLONE DERIVATIVE; QUINOLONE DERIVATIVE; SALICYLIC ACID; VITAMIN B COMPLEX;

ADOLESCENT; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOOD ALLERGY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROVOCATION TEST; SINGLE BLIND PROCEDURE; URTICARIA;

EID: 37849040470     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60409-7     Document Type: Article

References (33)

1. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983;74:102-109.
2. Settipane GA. Aspirin sensitivity and allergy. Biomed Pharmacother. 1988;42:493-498.
3. Sanchez-Borges M, Capriles-Hulett A. Atopy and NSAID sensitivity. J Allergy Clin Immunol. 1997;100:143-144.
4. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000;84:101-106.
5. Hoigne R, Schlumberger HP, Vervloet D, Zoppi M. Epidemiology of allergic drug reactions. Monogr Allergy. 1993;31:147-170.
6. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995;15:179-194.
7. Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. TiPS. 1997;18:30-34.
8. Nettis E, Marcandrea M, Ferrannini A, Tursi A. Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema. Immunopharmacol Immunotoxicol. 2001;23:343-354.
9. Nettis E, Di Paola R, Napoli G, Ferrannini A, Tursi A. Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria. Allergy. 2002;5:442-445.
10. Papa G, Romano A, Del Bono A, et al. Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 1997;78:74-78.
11. Nettis E, Di Paola R, Ferrannini A, Tursi A. Meloxicam in hypersensitivity to NSAIDs. Allergy. 2001;56:803-804.
12. Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2005;95:438-442.
13. Nettis E, Di Paola R, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2002;88:331-334.
14. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short term and long term tolerability of rofecoxib in patients with prior reactions to NSAIDs. Ann Allergy Asthma Immunol. 2005;94:29-33.
15. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol. 2005;94:34-38.
16. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87:201-204.
17. Asero R. Tolerability of rofecoxib. Allergy. 2001;56:916-917.
18. Boehncke S, Boehncke WH. Tolerance of coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). Dtsch Med Wochenschr. 2005;130:2249-2252.
19. Viola M, Quaratino D, Volpetti S, Gaeta F, Romano A. Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 2006;117:1189-1191.
20. Barton S, Langeland F, Snabes M, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology. 2002;96:306-314.
21. Stoltz R, Harris S, Kuss M, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol. 2002;97:65-71.
22. Mehlisch DR, Desjardins PJ, Daniels S, Hubbard RC. The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain. J Am Dent Assoc. 2004;135:1578-1590.
23. Looney Y, O'Shea A, O'Dwyer R. Severe bronchospasm after parenteral parecoxib: cyclooxygenase-2 inhibitors: not answer yet. Anesthesiology. 2005;102:473-475.
24. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cylooxigenase-2 inhibitor in a patient who had a reaction to a cylooxigenase-1 inhibitor. N Engl J Med. 2001;345:1856.
25. Charandeep K, Rasimi S, Amrinder JK. Fixed drug eruption of rofecoxib with cross-reactivity to sulfonamides. Dermatology. 2001;203:351.
26. Sarkar R, Kaur C, Kanwar AJ. Erythema multiforme due to rofecoxib. Dermatology. 2002;204:304-305.
27. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Aseptic meningitis associated with rofecoxib. Arch Intern Med. 2002;162:713-715.
28. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitor. J Allergy Clin Immunol. 2002;109:370.
29. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy. 2002;32:397-400.
30. Viola M, Quaratino D, Gaeta F, Caruso C, Valluzzi R, Romano A. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol. 2007;143:103-108.
31. Viola M, Quaratino D, Gaeta F, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol. 2005;137:145-150.
32. Bochenek G, Nizankowska E, Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 1996;51:16-23.
33. Asero R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol. 1999;82:554-558.